Veröffentlichungen

Dr. Holger G. Hass
Chefarzt
Facharzt für Innere Medizin, Hämatologie und internistische Onkologie, Gastroenterologie, Hepatologie und Palliativmedizin

 

Originalarbeiten (Zeitschriften mit Gutachtersystem)

Hass HG, Vogel U, Scheurlen M, Jobst J. Gene-expression Analysis Identifies Specific Patterns of Dysregulated Molecular Pathways and Genetic Subgroups of Human Hepatocellular Carcinoma. Anticancer Res. 2016 Oct; 36(10):5087-5095.

Hass HG, Muthny F, Stepien J, Lerch J, von der Marwitz C, Schröck R, Berger D, Tripp J. Wirkungen der telefonischen Nachsorge in der onkologischen Rehabilitationnach Brustkrebs – Ergebnisse einer randomisierten Studie. Die Rehabilitation (submitted)

Hass HG, Muthny F, Stepien J, Lerch J, von der Marwitz C, Schröck R, Berger D, Tripp J. Analyse von prognostischen Faktoren für den Reha-Erfolg und „Return-to-work“ in der onkologischen Rehabilitation. GMS Onkol Rehabil Sozialmed 2016; 5:Doc02 (20160615).

Hass HG, Jobst J, Scheurlen M, Vogel U, Nehls O. Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma. Anticancer Res. 2015 Apr;35(4):2021-8

Schelling M, Hass HG, Streitler T, Beer N, Roth R, Stepien J. Progredienzangst, Depression, Alter und Chemotherapie als potenzielle Prädiktoren der Aufmerksamkeitsleistung bei Mammakarzinom-Patientinnen. GMS Onkol Rehabil Sozialmed 2016; 5:Doc05 (20160715)

Hass HG, Jobst J, Vogel U, Scheurlen M, Nehls O. Overexpression of Tumor-Associated Trypsin Inhibitor (SPINK1/TATI) in Hepatitis C-Associated Hepatocellular Carcinoma: Potential Implications for Viral Hepatocarcinogenesis. Oncol Res Treat. 2014;37(12):732-8.

von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1607-14

Hass HG, Axmann D, Kunzmann V, Zabieglinski T. Inzidenz und Risikofaktoren des postoperativen Lymphödems bei Brustkrebspatientinnen in der onkologischen Rehabiliation – Analyse von 1030 Patientenfällen. GMS Onkol Rehabil Sozialmed 2014; 3:Doc11 (20141219)

Hass HG, Kunzmann V, Rinas N. Somatische Folgestörungen und Rehabilitationsbedarf bei Patientinnen mit Ovarialkarzinom – Unicenter-Erfahrungen bei 165 Patientinnen im Rahmen einer retrospektiven Studie. GMS Onkol Rehabil Sozialmed. 2013;2:Doc03.DOI: 10.3205/ors000008.

Tripp J, Schulte T, Schröck R, Hass HG, et al. Praxis Ziele und Zielerreichung in der onkologischen Rehabilitation aus Patienten- und Arztsicht Klinische Verhaltensmedizin und Rehabilitation 2012, 90: 98-109.

Hass HG, Axmann D, Wilhelm B, Holderied A, et al. Multimodales Therapiekonzept zur Behandlung der Adipositas in der onkologischen Rehabilitation – Unicenter-Erfahrungen im Rahmen einer prospektiven Studie. GMS Onkol Rehabil Sozialmed. 2012;1:Doc02.DOI: 10.3205/ors000002.

Faber G, Beinert T, Hass HG, Lotze C. Krebs und Ernährung. Onkologe 2011; 17: 906–912.

Stintzing S, von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011; 105: 206-11.

Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. J Clin Oncol. 2011; 29: 1050-58.

Hass HG, Smith U, Jäger C, Schäffer M, et al. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): single-center experience of 160 cases. Onkologie. 2011; 34: 682-6.

Hass HG, Bock T, Nehls O, Kaiser S. Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol. 2009; 44: 871-77.

Hass HG, Klein R, Nehls O, Kaiser S. Thyroid Disorders and Occurrence of Nonorgan-specific Autoantibodies (NOSA) in Patients With Chronic Hepatitis C Before and During Antiviral Induction Therapy With Consensus Interferon (Interferon Alfacon-1). J Clin Gastroenterol. 2009; 43: 470-76.

Hass HG, Denzlinger C. Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report. Z Gastroenterol. 2009; 47: 27-29.

Nehls O, Hass HG, Okech T, Zenner S, et al. Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. Int J Colorectal Dis. 2009; 24: 655-63. [Nehls O and Hass HG contributed equally to this work]

Hass HG, Nehls O, Jobst J, Frilling A, et al. Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol. 2008; 14: 2501-10.

Hass HG, Schmidt A, Nehls O, Kaiser S. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions. Oral Oncol. 2008; 44: 78-85.

Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008; 98: 309-15.

Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, et al. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007; 96: 1409-18.

Hass HG, Kaiser S. A 56-year-old female patient with Raynaud's syndrome, increased liver enzymes and neuropsychiatric symptoms. Dtsch Med Wochenschr. 2006; 131: 2213-16.

Nehls O, Hass HG, Weber P, Dette S, et al. Sarcoidosis mimicking cholangiocarcinoma. Endoscopy. 2006; 38: 65-66.

Hass HG, Kreysel C, Fischinger J, Menzel J, et al. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. World J Gastroenterol. 2005; 11: 5342-46.

Hass HG, Nägele T, Seeger U, Hösl F, et al. Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS). Z Gastroenterol. 2005; 43: 373-78.

Hass HG, Nehls O, Gregor M, Kaiser S, et al. Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses. Dig Liver Dis. 2004; 36: 367-68.

Naegele T, Seeger U, Hass HG, Kueker W, et al. Localized proton spectroscopy in hepatic encephalopathy: advantage of 3T high field for discrimination of glutamine and glutamate. Magnetom Flash 2004; 28: 50-53.

Nehls O, Klump B, Arkenau HT, Hass HG, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer. 2002; 87: 702-04.

 

Buchbeiträge

Hass HG, Bock CT. Hepatitis E: Morphology, Pathology and Prevention. In: Advances in Medicine and Biology, Vol 39. Eds. LV Berhardt. Nova Science Publishers 2011.

Hass HG. Hepatitis C. In: Leber und Gastrointestinaltrakt, Band 3 Tübinger Curricula. Eds. Häring, Balletshofer, Claussen. Thieme Verlag 2009.

Hass HG, Hösel F, Mader I, Seeger U, et al.. Subclinical and overt hepatic encephalopathy – Detection and treatment control by proton magnetic resonance spectroscopy (1H-MRS). In: Encephalopathy and nitrogen metabolism in liver failure. Eds. EA Jones, AJ Meijer, RAFM Chamuleau. Kluwer Academic Publishers 2003.